Boston Scientific Co. (NYSE:BSX) Shares Purchased by AAFMAA Wealth Management & Trust LLC

AAFMAA Wealth Management & Trust LLC raised its stake in shares of Boston Scientific Co. (NYSE:BSX) by 10.4% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 32,732 shares of the medical equipment provider’s stock after purchasing an additional 3,077 shares during the quarter. Boston Scientific comprises 1.2% of AAFMAA Wealth Management & Trust LLC’s portfolio, making the stock its 21st largest position. AAFMAA Wealth Management & Trust LLC’s holdings in Boston Scientific were worth $2,743,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Triad Wealth Partners LLC acquired a new stake in shares of Boston Scientific in the second quarter worth $26,000. First Foundation Advisors acquired a new stake in shares of Boston Scientific in the first quarter worth $25,000. Eagle Bay Advisors LLC increased its position in shares of Boston Scientific by 542.1% in the first quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 309 shares in the last quarter. Andra AP fonden acquired a new stake in shares of Boston Scientific in the second quarter worth $29,000. Finally, Lynx Investment Advisory acquired a new stake in shares of Boston Scientific in the second quarter worth $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. Morgan Stanley upped their target price on shares of Boston Scientific from $79.00 to $92.00 and gave the company an “overweight” rating in a research note on Monday, July 15th. Robert W. Baird increased their price objective on shares of Boston Scientific from $90.00 to $91.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Boston Scientific from $73.00 to $78.00 and gave the company a “hold” rating in a research note on Thursday, July 25th. StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Finally, Royal Bank of Canada increased their price objective on shares of Boston Scientific from $85.00 to $95.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $88.55.

Boston Scientific Stock Performance

Shares of BSX opened at $87.02 on Thursday. Boston Scientific Co. has a one year low of $49.15 and a one year high of $88.09. The company has a 50-day moving average of $82.03 and a two-hundred day moving average of $76.89. The stock has a market cap of $127.66 billion, a price-to-earnings ratio of 73.12, a PEG ratio of 2.87 and a beta of 0.80. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 EPS for the quarter, topping the consensus estimate of $0.58 by $0.04. The company had revenue of $4.12 billion during the quarter, compared to analysts’ expectations of $4.02 billion. Boston Scientific had a net margin of 12.00% and a return on equity of 16.59%. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period last year, the company posted $0.53 earnings per share. On average, equities research analysts expect that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the completion of the sale, the executive vice president now directly owns 37,468 shares in the company, valued at approximately $3,061,135.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CEO Michael F. Mahoney sold 162,777 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $84.63, for a total transaction of $13,775,817.51. Following the completion of the sale, the chief executive officer now directly owns 1,572,096 shares in the company, valued at approximately $133,046,484.48. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the transaction, the executive vice president now directly owns 37,468 shares in the company, valued at approximately $3,061,135.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 316,253 shares of company stock worth $26,714,298. 0.50% of the stock is owned by company insiders.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.